Plantamajoside: A potentially novel botanical agent for diabetes mellitus management

doi:10.4239/wjd.v16.i5.104311

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (25)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=23

May 15, 2025 (publication date) through Apr 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. May 15, 2025; 16(5): 104311
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.104311

Plantamajoside: A potentially novel botanical agent for diabetes mellitus management

Na Liu, Wei-Tao Yan, Kun Xiong

Na Liu, Wei-Tao Yan, Kun Xiong, Department of Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha 410013, Hunan Province, China

Author contributions: Liu N wrote the original draft; Yan WT reviewed and edited the manuscript; Xiong K was the senior author and provided supervision and validation of the writing; All authors have read and agreed to the published version of the manuscript.

Supported by the National Natural Science Foundation of China, No. 82303047, No. 82372507, No. 82172196 and No. 32401046; and Natural Science Foundation of Hunan Province, No. 2022JJ40801.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Kun Xiong, PhD, Director, Professor, Department of Anatomy and Neurobiology, School of Basic Medical Science, Central South University, No. 172 Tongzipo Road, Changsha 410013, Hunan Province, China. xiongkun2001@163.com

Received: December 18, 2024
Revised: February 8, 2025
Accepted: February 20, 2025
Published online: May 15, 2025
Processing time: 129 Days and 2.7 Hours

Core Tip

Core Tip: Diabetes mellitus (DM) is a global health challenge impacting millions of lives, necessitating the urgent development of effective therapeutic agents. Wang et al observed that plantamajoside (PMS), a bioactive component derived from traditional Chinese medicine, alleviates pancreatic tissue damage and protects β-cells from apoptosis by upregulating DNAJC1. This research underscores the potential of PMS in DM treatment and suggests that other regulated cell death pathways may also be involved in DM progression as modulated by PMS. Further investigations are essential to elucidate the underlying mechanisms and to expand our understanding of PMS as a therapeutic agent for DM.